Equities research analysts forecast that Vascular Biogenics Ltd (NASDAQ:VBLT) will report ($0.14) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Vascular Biogenics’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.13). Vascular Biogenics reported earnings per share of ($0.10) in the same quarter last year, which suggests a negative year over year growth rate of 40%. The company is scheduled to report its next quarterly earnings report on Thursday, March 26th.

According to Zacks, analysts expect that Vascular Biogenics will report full year earnings of ($0.52) per share for the current year, with EPS estimates ranging from ($0.53) to ($0.52). For the next year, analysts anticipate that the business will post earnings of ($0.56) per share, with EPS estimates ranging from ($0.61) to ($0.53). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Vascular Biogenics.

Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings results on Thursday, November 14th. The biopharmaceutical company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14). Vascular Biogenics had a negative net margin of 3,050.43% and a negative return on equity of 37.19%. The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.24 million.

A number of research firms recently issued reports on VBLT. Chardan Capital restated a “buy” rating and issued a $3.25 target price on shares of Vascular Biogenics in a report on Friday, January 10th. ValuEngine downgraded shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Tuesday, January 14th. Roth Capital restated a “buy” rating on shares of Vascular Biogenics in a report on Thursday, January 2nd. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Vascular Biogenics in a report on Friday, November 15th. Finally, Zacks Investment Research downgraded shares of Vascular Biogenics from a “buy” rating to a “hold” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $2.38.

A hedge fund recently raised its stake in Vascular Biogenics stock. Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Vascular Biogenics Ltd (NASDAQ:VBLT) by 66.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,500 shares of the biopharmaceutical company’s stock after buying an additional 15,000 shares during the quarter. Ladenburg Thalmann Financial Services Inc. owned 0.10% of Vascular Biogenics worth $49,000 at the end of the most recent quarter. 4.67% of the stock is owned by institutional investors and hedge funds.

Vascular Biogenics stock traded up $0.02 during trading on Friday, reaching $1.43. The company had a trading volume of 130,960 shares, compared to its average volume of 117,119. Vascular Biogenics has a 12-month low of $0.93 and a 12-month high of $1.90. The stock’s 50 day moving average price is $1.24 and its two-hundred day moving average price is $1.26. The firm has a market capitalization of $50.59 million, a price-to-earnings ratio of -2.92 and a beta of -0.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.49 and a current ratio of 5.49.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Read More: What is the Gross Domestic Product (GDP)?

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.